Inogen Launches Rove 4 Portable Oxygen Concentrator, Delivering the Highest Oxygen Output in the Lightest Weight 4-Setting POC
October 08 2024 - 7:30AM
Business Wire
Inogen, Inc. (Nasdaq: INGN), a medical technology company
offering innovative respiratory products for use in the homecare
setting, today announced that it has commenced the U.S. market
release of the Inogen® Rove 4™ Portable Oxygen Concentrator.
With an additional, fourth flow setting delivering up to
840ml/min of medical grade oxygen, in a lightweight user-friendly
design of less than 3 lbs1 and three battery configurations
providing up to 5 hours and 45 minutes of operation2, the
versatility of Rove 4 empowers patients with choices that may help
them with normal activities of daily living.
“We are pleased to announce the launch of Rove 4, a meaningful
step forward in our intent to serve patients in need of oxygen
therapy while allowing them to remain ambulatory,” said Kevin
Smith, President and Chief Executive Officer. “This is an important
milestone, and we are excited to work with patients and prescribers
to deliver the positive impact of Rove 4 technology.”
According to Neil MacIntyre, MD, of Duke University Medical
Center, “It is exciting to see the continuing innovation of
portable oxygen concentrators to help advance the ambulation of
long-term oxygen therapy patients. The Inogen Rove 4 should play a
meaningful role on this journey.”
The Rove 4 utilizes Inogen’s patented pulse-dose Intelligent
Delivery Technology®3. This technology provides unparalleled
triggering sensitivity to quickly detect a breath and deliver
oxygen within the first 250 milliseconds of the inspiration, where
oxygen has the most effect on lung gas exchange.
Designed for reliability, the Rove 4 offers a best-in-class
expected service life of up to 8 years4.
1 2.9 lbs when used with standard battery. 2 At setting 1. 3
Pulse-dose based Intelligent Delivery Technology® ensures that
oxygen therapy is delivered efficiently and effectively in all
modes of use. 4 When used for less than 8 hours per day.
About Inogen
Inogen, Inc. (Nasdaq: INGN) is a leading global medical
technology company offering innovative respiratory products for use
in the homecare setting. Inogen supports patient respiratory care
by developing, manufacturing, and marketing innovative
best-in-class portable oxygen concentrators used to deliver
supplemental long-term oxygen therapy to patients suffering from
chronic respiratory conditions. Inogen partners with patients,
prescribers, home medical equipment providers, and distributors to
make its oxygen therapy products widely available allowing patients
the chance to remain ambulatory while managing the impact of their
disease.
For more information, please visit www.inogen.com.
Inogen has used, and intends to continue to use, its Investor
Relations website, http://investor.inogen.com/, as a means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, among others, statements with respect to the
announced changes to management; statements concerning or implying
Inogen’s future financial performance; the ability of management
personnel to contribute to the execution of Inogen’s strategic
plans and goals. Any statements contained in this communication
that are not statements of historical fact may be deemed to be
forward-looking statements. Words such as “believes,”
“anticipates,” “plans,” “expects,” “will,” “intends,” “potential,”
“possible,” and similar expressions are intended to identify
forward-looking statements. Forward-looking statements are subject
to numerous risks and uncertainties that could cause actual results
to differ materially from currently anticipated results, including
but not limited to, risks related to its announced management and
organizational changes, and risks arising from the possibility that
Inogen will not realize anticipated future financial performance or
strategic goals. In addition, Inogen's business is subject to
numerous additional risks and uncertainties, including, among
others, risks relating to market acceptance of its products;
competition; its sales, marketing and distribution capabilities;
its planned sales, marketing, and research and development
activities; interruptions or delays in the supply of components or
materials for, or manufacturing of, its products; seasonal
variations; unanticipated increases in costs or expenses; risks
associated with international operations; and the possibility that
Inogen will not realize anticipated revenue from recent or future
technology acquisitions or that expenses and costs related thereto
will exceed Inogen’s expectations. Information on these and
additional risks, uncertainties, and other information affecting
Inogen’s business operating results are contained in its Annual
Report on Form 10-K for the period ended December 31, 2023, its
Quarterly Report on Form 10-Q for the calendar quarter ended June
30, 2024 and in its other filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date hereof. Inogen disclaims any obligation to update these
forward-looking statements except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241008928593/en/
ir@inogen.net
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Dec 2023 to Dec 2024